Loading...
XNAS
REVBW
Market cap793kUSD
Jun 02, Last price  
0.01USD
1D
12.61%
1Q
-21.64%
IPO
-94.85%
Name

Revelation Biosciences Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-15.04b
L+12,505,543.06%
-3,638-1,630,500-11,986,837-10,794,587-120,254-15,038,536,000
CFO
-18.32b
L+251,348.76%
0-215,074-11,090,573-11,219,396-7,286,286-18,321,276,000
Earnings
Aug 07, 2025

Profile

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
IPO date
Oct 08, 2020
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
7,975,109
8,682
10,905
Unusual Expense (Income)
NOPBT
(7,975,109)
(8,682)
(10,905)
NOPBT Margin
Operating Taxes
(35)
Tax Rate
NOPAT
(7,975,109)
(8,682)
(10,870)
Net income
(15,038,536)
12,505,543.06%
(120)
-98.89%
(10,795)
-9.95%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,417
14,025
(3,191)
BB yield
-685.13%
-408.37%
2.97%
Debt
Debt current
(2,911)
Long-term debt
Deferred revenue
Other long-term liabilities
554
Net debt
(6,499,018)
(11,992)
(8,164)
Cash flow
Cash from operating activities
(18,321,276)
(7,286)
(11,219)
CAPEX
(19)
(4)
Cash from investing activities
(19,171)
Cash from financing activities
12,847,764
14,025
15,198
FCF
(8,039,886)
(10,693)
(9,006)
Balance
Cash
6,499,018
11,992
5,253
Long term investments
Excess cash
6,499,018
11,992
5,253
Stockholders' equity
(40,505,637)
(25,467)
(25,346)
Invested Capital
47,125,773
32,115
23,487
ROIC
ROCE
586.64%
EV
Common stock shares outstanding
1,715
229
538
Price
0.46
-96.93%
15.02
-92.47%
199.61
-98.14%
Market cap
791
-76.98%
3,434
-96.80%
107,487
-97.29%
EV
(6,498,227)
(8,557)
99,323
EBITDA
(7,947,186)
(8,657)
(10,879)
EV/EBITDA
0.82
0.99
Interest
35
Interest/NOPBT